<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34139704</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1660-2862</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1-2</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Neuro-degenerative diseases</Title><ISOAbbreviation>Neurodegener Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence of Gastrointestinal Symptoms, Severity of Dysphagia, and Their Correlation with Severity of Amyotrophic Lateral Sclerosis in a Mexican Cohort.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>47</EndPage><MedlinePgn>42-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000517613</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Our study aimed to identify the prevalence and severity of gastrointestinal (GI) symptoms and dysphagia in patients with amyotrophic lateral sclerosis (ALS) and to assess whether a correlation exists between these symptoms and the severity of ALS progression.</AbstractText><AbstractText Label="METHODS">The presence and severity of GI symptoms and dysphagia were identified by means of the Gastrointestinal Symptom Rating Scale (GSRS) and the Functional Outcome Swallowing Scale (FOSS). The Revised ALS Functional Rating Scale (ALSFRS-R) was utilized to determine the severity of ALS. Analysis of data was performed with Spearman correlations in semi-qualitative variables of clinical scales. ALSFRS-R scores were divided into 2 categories: those with mild to moderate ALS (&#x2265;40-30 points) and patients with moderate to advanced ALS (29-&#x2264;20 points).</AbstractText><AbstractText Label="RESULTS">We studied 43 patients with definite ALS. The most frequent GI symptoms were constipation (60.5%), rectal tenesmus (57.5%), hard stools (55.0%), and borborygmus (42.5%). The moderate to advanced ALS stage was correlated with constipation (r = 0.334; p = 0.028), acid regurgitation (r = 0.384; p = 0.013), eructation (r = 0.334; p = 0.032), rectal tenesmus (r = 0.498; p = 0.001), and functional dysphagia (r = 0.656; p = &lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">Early detection of these GI symptoms can guide timely therapeutic decisions to avoid weight loss, a predictor for worse prognosis. This study highlights the relevance of the detection of these symptoms in ALS patients who score &#x2264;29 points in the ALSFRS-R scale to establish an appropriate treatment, prevent systemic complications, provide more comfort, and improve quality of life.</AbstractText><CopyrightInformation>&#xa9; 2021 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parra-Cantu</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico, caro_parra38@hotmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Clinic, Institute of Neurology and Neurosurgery, Zambrano Hellion Hospital, San Pedro Garza Garcia, Mexico, caro_parra38@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaldivar-Ruenes</LastName><ForeName>Arnulfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tecnologico de Monterrey, School of Social Sciences and Government, Monterrey, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Vazquez</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Internal Medicine, Zambrano Hellion Hospital, San Pedro Garza Garcia, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Hector R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALS Clinic, Institute of Neurology and Neurosurgery, Zambrano Hellion Hospital, San Pedro Garza Garcia, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>0.6084/m9.figshare.14707329.v1</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurodegener Dis</MedlineTA><NlmUniqueID>101189034</NlmUniqueID><ISSNLinking>1660-2854</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Gastrointestinal symptoms</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>20</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34139704</ArticleId><ArticleId IdType="doi">10.1159/000517613</ArticleId><ArticleId IdType="pii">000517613</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>